Ulcerative colitis candidate and long-term vision

For decades, drug discovery has shifted away from nature and toward biology-first approaches. Viswa Colluru believes that shift was a catastrophic mistake. His company, Enveda Biosciences, has raised over $500 million to build a “search engine for nature’s chemistry.” The mission is personal: he grew up around his father’s pharmacy in India and later lost his mother to a treatable cancer whose medicine his family couldn’t afford. Many life-changing medicines, including morphine, aspirin, and metformin, originated in nature, but there has never been a reliable, scalable way to systematically explore its chemistry. Colluru founded Enveda in 2019 with $55,000 of his own savings to change that. The company has since identified 18 drug candidates, with three now in clinical trials.

In our conversation, we explore:

• Why the pharmaceutical industry abandoned nature (and why that was a massive mistake)
• How Enveda built a system to decode unknown molecules in nature
• The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work
• Why old ideas, from immunotherapy to natural products, often hold the most latent potential
• How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million
• Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis
• Why first-in-class medicines capture the vast majority of returns in pharma
• What competitive table tennis taught him about building companies

—

Thank you to the partners who make this possible

Brex: The intelligent finance platform.

Ahrefs Brand Radar: Find your brand in AI results.

Persona: Trusted identity verification for any use case.

—

Timestamps

(00:00) Introduction to Viswa Colluru

(03:57) His father’s pharmacy and early exposure to Western and Ayurvedic medicine

(07:06) Early pull toward technology

(09:29) His mother’s leukemia diagnosis

(14:24) Studying Biotechnology

(16:07) Graduate school

(17:55) Studying immunotherapy when it was unfashionable

(24:23) Innovation vs. novelty

(27:24) Lessons from table tennis

(32:05) Joining Recursion

(37:10) Learning urgency and courage

(40:42) What launched Enveda

(45:40) The limits of reductionist drug discovery

(49:53) Chemistry-first approach

(52:17) Raising $225K and investing $55K personally

(56:04) Initial studies and targets

(1:04:30) Three categories of leading drugs: Eczema, obesity, ulcerative colitis

(1:13:27) Why GLP-1s are not the whole answer

(1:18:27) Enveda’s long-term vision

(1:21:31) Book recommendation

—

Follow Viswa Colluru

LinkedIn: https://www.linkedin.com/in/viswacolluru

X: https://x.com/viswacolluru

—

Resources and episode mentions: https://www.generalist.com/p/the-future-of-drug-discovery

—

Production and marketing by penname.co. For inquiries about sponsoring the podcast, email jordan@penname.co.